Health Care

Sunrise Senior Living is in a $845 million deal to be purchased by Health Care REIT.

Criticism is intensifying about the second-largest U.S. health insurer’s poor stock performance, weak quarterly earnings and bleak outlook that includes a predicted loss of some 900,000 members, leading calls for the ouster of CEO Angela Braly.

AstraZeneca hired Pascal Soriot from rival Roche to be its new chief executive, hoping his veteran experience helps revive the drugmaker.

Aetna is buying rival Coventry Health Care for $5.7 billion to build its Medicare business.

With the prevalence of diabetes growing at a quick pace and health-care reform that could widen access to insurance for millions of people looming, a bitter battle among drug makers is intensifying. 

Amylin Pharmaceuticals shares rose as much as 51% on Wednesday on reports that the company rejected a $3.5 billion unsolicited takeover bid from Bristol-Myers Squibb.

Johnson & Johnson forecast 2016 sales below analysts' estimate and reported a 2.4 percent drop in sales for the fourth quarter, hurt by a strong dollar.

Johnson & Johnson is set to pay more than $1 billion to resolve a civil investigation into the marketing of its Risperdal antipsychotic drug.

UnitedHealth projected a 5% increase in 2013 earnings, but Wall Street had been anticipating stronger growth from the largest U.S. private health insurer.

The Supreme Court on Monday revived a legal challenge to President Obama's Affordable Care Act filed by Liberty University on religious grounds. 

Documents show the Food and Drug Administration took 684 days to issue a warning letter after uncovering serious issues at the pharmacy at the center of the recent U.S. meningitis outbreak.

Merck upped its quarterly dividend by a penny to 43 cents per share Tuesday, citing optimism about the future. 

AstraZeneca agreed to buy Bristol-Myers Squibb’s (NYSE:BMY) stake in their diabetes joint venture for up to $4.1 billion.

AstraZeneca agreed to buy Bristol-Myers Squibb’s (NYSE:BMY) stake in their diabetes joint venture for up to $4.1 billion.

Rite Aid revealed slightly higher third-quarter sales on Thursday but axed its outlook.  

CVS Caremark and Cardinal Health crafted a deal to form the largest generic drug sourcing operation in the U.S.

UnitedHealth Group unveiled earnings and revenue projections for 2014 that missed Wall Street’s expectations.

The $2.1 billion acquisition of Apria's Coram is aimed at bolstering CVS Caremark's specialty pharmacy business. 

While a battle rages over technical issues on the ACA site, questions are emerging about the safety of data entered into its systems.